Y Mabs Therapeutics Inc (YMAB)

02:25 AM

What drives Y mAbs Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

02:25 AM

01:59 AM

What analysts say about Y mAbs Therapeutics Inc. stockBreakthrough investment results - jammulinksnews.com

01:59 AM

12:38 PM

How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com

12:38 PM

Jul 22, 2025

Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Y mAbs Therapeutics Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional

Jul 21, 2025

Jul 15, 2025

Y-Mabs Therapeutics Elects New Director at Annual Meeting - TipRanks

Jul 15, 2025

Jul 15, 2025

Y-mAbs Therapeutics announces results of annual shareholder meeting votes - Investing.com

Jul 15, 2025

Jul 15, 2025

What makes Y mAbs Therapeutics Inc. stock price move sharplySafe and Smart Investment Picks - Newser

Jul 15, 2025

Jul 15, 2025

Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser

Jul 15, 2025

Jul 14, 2025

2nd Circ. Affirms Biotech Founder's Win In Trading Suit - Law360

Jul 14, 2025

Jul 11, 2025

Transcript : Y-mAbs Therapeutics, Inc.Shareholder/Analyst Call - MarketScreener

Jul 11, 2025

Jul 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Jul 04, 2025

Jul 02, 2025

YMAB SEC FilingsY-Mabs Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 02, 2025

Jun 25, 2025

Is Y-mAbs Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025

Jun 15, 2025

Cantor Fitzgerald Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Overweight Recommendation - MSN

Jun 15, 2025

Jun 14, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles - Investing.com India

Jun 14, 2025

Jun 13, 2025

Y-mAbs Therapeutics’ SWOT analysis: oncology biotech stock faces growth hurdles By Investing.com - Investing.com South Africa

Jun 13, 2025

Jun 12, 2025

Millennium Management LLC Cuts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025

Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 7,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 12, 2025

Jun 11, 2025

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate - Yahoo Finance

Jun 11, 2025

Jun 11, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 11, 2025

Jun 09, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 09, 2025

Jun 08, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE - Defense World

Jun 08, 2025

Jun 05, 2025

BNP Paribas Financial Markets Has $38,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 05, 2025

Jun 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Jane Street Group LLC - Defense World

Jun 04, 2025

Jun 03, 2025

YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Class Action Pending - ACCESS Newswire

Jun 03, 2025

Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $179,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jun 02, 2025

Jun 02, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Deutsche Bank AG - Defense World

Jun 02, 2025

May 30, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer - Defense World

May 30, 2025

May 29, 2025

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB) - The Globe and Mail

May 29, 2025